Results 21 to 30 of about 2,566,443 (193)
Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review [PDF]
Journal of General Internal Medicine, 2017 Urate-lowering therapy (ULT) is associated with low rates of adherence, leading to a potential risk of relapse of gouty arthritis, tophi, or urolithiasis. Our main aim was to identify the recurrence of gouty arthritis, tophi, or urolithiasis after discontinuation of ULT.
Beslon, Virginie +5 more
openaire +5 more sources
Kidney & Blood Pressure Research, 2018 Current urate-lowering therapy (ULT) includes three direct acting drugs (allopurinol, febuxostat, Rasburicase) and at least four ‘indirect’ drugs with other important targets (canagliflozin, losartan, fenofibrate and sevelamer).
Davide Viggiano +5 more
doaj +2 more sources
Arthritis & Rheumatology, 2022 ObjectiveTo determine whether a therapeutic approach of intensive serum urate lowering results in improved bone erosion scores in patients with erosive gout.MethodsWe undertook a 2‐year, double‐blind randomized controlled trial of 104 participants with erosive gout who were receiving serum urate–lowering therapy orally and who had serum urate levels of
Nicola Dalbeth +12 more
openaire +3 more sources
Clinical interventions to improve adherence to urate-lowering therapy in patients with gout: a systematic review [PDF]
International Journal of Pharmacy Practice, 2022 The aim of this study was to systematically review and compare the quantitative effect of clinical interventions designed to improve adherence to urate-lowering therapy.
Dyfrig A. Hughes +2 more
exaly +2 more sources
The Effect of Decrease in Serum Urate for the Risk of Gout Flares During Urate-Lowering Therapy Initiation Among Chinese Male Gout Patients: A Prospective Cohort Study. [PDF]
J Inflamm Res, 2023 Lei Pang,1– 4,* Xiaomei Xue,1– 4,* Yuwei He,1– 4 Can Wang,1– 4 Lin Han,1– 4 Maichao Li,1– 4 Han Qi,1– 4 Changgui Li,1– 4 Jie Lu1– 4 1Shandong Provincial Clinical Research Center for Immune Diseases and Gout, the Affiliated Hospital of Qingdao ...
Pang L +8 more
europepmc +2 more sources
International Journal for Equity in Health, 2021 Background Gout is a painful chronic disease which disrupts work and family life and can lead to chronic joint damage. Pacific people in Aotearoa/New Zealand experience significant inequities, with over three times the gout prevalence of the non-Pacific ...
Malakai Ofanoa +8 more
doaj +2 more sources
Behavioral Characteristics of Gout Patients and Their Impact on the Results of Urate Lowering Therapy [PDF]
Acta Biomedica Scientifica, 2021 Background. Gout is frequently accompanied by hypertension, obesity, and/or impaired glucose tolerance, which are often complicated with heavy smoking and dietary violations, especially in male patients.Objective.
J. Chen +4 more
doaj +2 more sources
Prevention of arthritis attacks in the use of urate-lowering therapy in patients with gout [PDF]
Научно-практическая ревматология, 2019 During the first months after initiation of urate-lowering therapy in patients with gout, the risk of exacerbating arthritis substantially increases, frequently causing them to refuse this treatment.
M. N. Chikina
doaj +2 more sources
Journal of NephrologyInternational audienceBackground: Hyperuricemia is a hallmark of gout and a suspected risk factor for the progression of chronic kidney disease (CKD). However, the impact of urate-lowering therapy on CKD progression is subject to debate. The objective of
Sophie Liabeuf +2 more
exaly +2 more sources
Revisiting the Ethics of Urate-Lowering Therapy Clinical Trials for Gout Management. [PDF]
Arthritis RheumatolThe early 2000s saw a wave of randomized controlled trials (RCTs) of new urate-lowering therapies (ULTs) used in the management of gout. These trials compared the novel medications with placebo or relatively low doses of allopurinol.
Stamp LK, Ho D, Dalbeth N.
europepmc +3 more sources